GILD - Gilead Sciences, Inc.
68.75 -0.09 (-0.13%)
After hours: 5:55PM EDT
| Previous Close | 69.38 |
| Open | 69.13 |
| Bid | 68.75 x 2200 |
| Ask | 69.07 x 1800 |
| Day's Range | 68.70 - 69.48 |
| 52 Week Range | 60.32 - 79.61 |
| Volume | 4,013,715 |
| Avg. Volume | 6,546,087 |
| Market Cap | 87.533B |
| Beta (3Y Monthly) | 1.14 |
| PE Ratio (TTM) | 15.19 |
| EPS (TTM) | 4.53 |
| Earnings Date | Jul 23, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | 2.52 (3.68%) |
| Ex-Dividend Date | 2019-06-13 |
| 1y Target Est | 79.81 |
- Business Wire•4 hours ago
Gilead and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies
Gilead Sciences, Inc. (GILD) and Carna Biosciences Inc. (JASDAQ:4572) today announced that the companies have entered into a research and development collaboration to develop and commercialize small molecule compounds in immuno-oncology and to access Carna’s proprietary lipid kinase drug discovery platform. Under the terms of the license agreement, Gilead will license from Carna worldwide rights to develop and commercialize inhibitors against an undisclosed immuno-oncology target. In connection with this agreement, Carna will receive an upfront payment of $20 million and is eligible to receive up to an additional $450 million in potential milestone payments upon achievement of certain development and commercial milestones.
- MarketWatch•3 days ago
This would be the worst-case scenario for health stocks, according to UBS
Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.
- Zacks•4 days ago
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Gilead Sciences (GILD) closed at $69.38 in the latest trading session, marking a +1.18% move from the prior day.
- Zacks•4 days ago
3 Big Biotechs Hold Growth Potential in Second Half of 2019
We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.
- Zacks•4 days ago
Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up
Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.
- Zacks•5 days ago
Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs
Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
- InvestorPlace•6 days ago
3 Large-Cap Biotech Stocks to Buy for Massive Gains
Do you want to find the next Apple (NASDAQ:AAPL) or Amazon (NASDAQ:AMZN)? My advice is that you should set your sights lower, not higher and put some cash to work in three down, but not out heavyweight biotech stocks for the next big thing in investing. Let me explain.It has been a good week so far for the broader markets. The Nasdaq Composite, S&P 500 and Dow Jones Industrial Average have broken out of short bases barely discernible on the weekly chart and back within spitting distance of their respective all-time-highs following May's abrupt correction. It has been a nice period for biotech stocks as well.The Vaneck Vectors Biotech ETF (NYSEARCA:BBH) is up nearly 3.50% through Tuesday's close compared to gains of roughly 1% to 2% for the broader averages. But as any investor with a passing interest in the markets knows, the outperformance in biotech stocks has been anything but a recurring theme these past couple years.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer The good news is markets are cyclical. Even legendary investments such as AMZN or the sacrosanct AAPL stock have been known to correct for periods lasting not weeks, but months and even years. With that in mind, it's time to consider adding these three large-cap biotech stocks into your portfolio. Amgen (AMGN) Click to EnlargeAmgen (NASDAQ:AMGN) is a biotech heavyweight that also happens to be the sector's largest capitalization outfit with a valuation of about $110 billion.Following a recent sales and earnings beat, this reasonably-priced biotech giant, which pays investors nearly 3.5% in quarterly dividends, has now put together a bottom on the monthly price chart.Specifically, AMGN stock has formed a confirmed pivot low, which reaffirms its longstanding uptrend after a correction of several months. And with plenty of lateral, angular and Fibonacci price supports, as well as an oversold crossover signal to confirm the bottom, this biotech stock is a buy today.The TradeBuy AMGN stock at current prices. Set a stop-loss beneath support below $160, but expect shares to hit new highs in 2019's second half. Gilead Sciences (GILD) Click to EnlargeIt has been a rough few years for Gilead Sciences (NASDAQ:GILD), one the sector's largest names, but things are looking up for GILD stock lately.A recent earnings report that reiterated the company's full-year guidance and offered a modest year-over-year uptick in sales and profits looks promising for Gilead shares, which have been absolutely pummeled over the last four years.Technically, shares are trading slightly above multiple inside candlesticks following a double bottom pattern of about one and a half years. With the formation finding support off the 50% retracement level and a supportive-looking stochastics set-up signaling better months and years ahead, GILD stock looks good to buy right now. * 10 'Buy-and-Hold' Stocks to Own Forever The TradeBuy GILD stock at current levels with an initial stop-loss below $59. On the upside, $85 - $90 looks like a good area for profit-taking while allowing this down-and-out value stock some room to run. Biogen (BIIB) Click to EnlargeMuch like GILD stock, shares of sector heavyweight Biogen (NASDAQ:BIIB) have been under extreme technical duress the past few years.Most recently, the pain in BIIB stock came after the company's announcement that it was axing a drug to treat Alzheimer's following poor results. The suffering came despite the fact that BIIB posted stronger-than-forecast results in late April.On the price chart, this biotech stock's technical beating since 2015 has resulted in a possible four-year long double-bottom pattern that's finding support in-between the 50% and 62% retracement levels. Coupled with an oversold stochastics that is a hair's breadth away from signaling a bullish crossover, confirmation of the pivot low looks imminent.The TradeBuy BIIB stock above May's candle high of $238.17 to confirm the pattern bottom. I'd suggest an initial stop beneath $214 and to take partial profits in-between $300 - $310.Disclosure: Investment accounts under Christopher Tyler's management currently do not own positions in any of the securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Value Stocks to Buy for the Second Half * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer * 6 Chip Stocks Staring At Big Headwinds in 2019 Compare Brokers The post 3 Large-Cap Biotech Stocks to Buy for Massive Gains appeared first on InvestorPlace.
- American City Business Journals•6 days ago
Why Gilead could pay more than $2 billion in deal with this small S.F. biotech
Founded by three professors from UC Berkeley and UCSF, Nurix's protein-degradation approach to cancer, and potentially other diseases, could stop cancer in its tracks.
- Zacks•6 days ago
Big Drugmakers That May Tread the M&A Path After Pfizer
There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
- MarketWatch•6 days ago
Gilead strikes deal with Nurix Therapeutics to tackle disease-causing proteins
Gilead Sciences Inc. is partnering with Nurix Therapeutics, a biotech working on drugs to destroy disease-causing proteins, the companies announced Wednesday. Under the terms of the multi-year deal, Gilead will have the option to license certain drug candidates from Nurix, and Nurix will have the option to develop up to two programs with Gilead in the U.S., splitting the costs, U.S. sales and losses of those drugs. The deal excludes Nurix's lead drug program, for which Nurix will retain all rights. Nurix will receive an upfront payment of $45 million and is eligible to receive up to approximately $2.3 billion in additional milestone payments and royalties, the companies said. "There are many molecular targets involved in disease pathways that have traditionally been challenging to manipulate using conventional approaches," said John McHutchison, Gilead's chief scientific officer and head of research and development. "Nurix's innovative protein degradation discovery technology provides Gilead with a new strategy to interrogate these drug targets, as we continue to build a pipeline of small molecule therapeutics for patients with cancers and other diseases." Nurix's drug platform targets the ubiquitin system, a natural way the body degrades normal and disease-associated proteins. The company is working on ways to manipulate this system to fight diseases in immuno-oncology and hematology. Shares of Gilead have gained 9% so far this year, while the S&P 500 has gained 16.4%.
- Business Wire•6 days ago
Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases
Gilead Sciences, Inc. (GILD) and Nurix Therapeutics, Inc., a company discovering drugs that harness the body’s natural process to control protein levels, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases. Dysregulated and/or mutated proteins play a central role in the development and progression of many human diseases. Nurix’s technology platform is focused on the manipulation of the ubiquitin system and its component E3 ligases, the key enzymes responsible for controlling protein levels in human cells.
- InvestorPlace•7 days ago
3 Big Stock Charts for Tuesday: McKesson, Dish Network and Gilead Sciences
It was anything but a high-conviction win, but stocks managed to hold onto a piece of Monday's gain. The S&P 500 ended the day up 0.09%, just barely able to hang on to its place above a pivotal support level.Source: Allan Ajifo via Wikimedia (Modified)Facebook (NASDAQ:FB) did a great deal of the heavy lifting, rallying more than 4% on the heels of news that it was planning to launch its own cryptocurrency. Chesapeake Energy (NYSE:CHK) wasn't far behind though, gaining more than 3% thanks to rebounding natural gas prices, which hit multi-month lows just a few days back. A multi-week selloff from CHK set the stage rather nicely though.Advanced Micro Devices (NASDAQ:AMD) led the losers, off almost 4% after Goldman Sachs posted some broadly bearish thoughts on software names. AMD was guilty by indirect association though, and is teetering on its worst losing streak in eight months.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Best Index Funds to Buy and Hold Headed into Tuesday's trading action though, it's the stock charts of McKesson (NYSE:MCK), Gilead Sciences (NASDAQ:GILD) and Dish Network (NASDAQ:DISH) that are worth the closest looks. Here's why, and what's likely to happen next. Dish Network (DISH)On Tuesday of last week we pointed out Dish Network was putting the finishing touches on a move above a significant technical ceiling. But, the nature of the effort was less than convincing. It was going to require a confirmation of sorts that DISH shares were ready to remain above that resistance.We moved toward that goal over the course of last week, but yesterday we effectively sealed the deal. The shape and placement of Monday's bar says the bulls mean business. Now that the heavy lifting is done the stock has a lot of room to continue recovering its 2017 and 2018 losses. Click to Enlarge * The ceiling in question is right around $36.90, plotted in yellow on both stock charts. That was a resistance level in late May, but as the weekly chart shows, it was a huge problem in mid-2018. * Monday's bar is ideal. A decent open only had to kiss the former technical ceiling to drive the stock to its highest close in over a year. * Bolstering the bullish argument is how much volume took shape behind yesterday's gain. But, this also wasn't the first time we've seen a volume surge behind major forward progress. The bulls are starting to form, en masse. * The weekly chart puts it all in perspective. There's not another major technical ceiling in sight until the $66.50 area, marked in blue. McKesson (MCK)A little over a week ago McKesson was featured as a budding breakout candidate. It has crossed back above all of its key moving average lines, and though a rather important technical ceiling remained above, the momentum was encouraging.That resistance line ended up being tested as expected, although MCK shares failed to clear it. They're still in the hunt for that breakout move though, and now they're even closer to starting it with an ideal bull signal. * 7 Top-Rated Biotech Stocks to Invest In Today Click to Enlarge * The resistance level to watch is the line that traces all the major peaks going back to October, including last week's. It's plotted in yellow on both stock charts. * It's evident on both charts, but the weekly chart puts the current converging wedge pattern in perspective. This is one of the best chances we've seen of reversing a multi-year selloff. * Although the last one didn't offer much help, the purple 50-day moving average line is about to cross above the white 200-day line. That will draw a crowd of bulls no matter what, but especially if McKesson can break above its falling resistance line. Gilead Sciences (GILD)Take it with a grain of salt, as we've seen it before, to no avail. But, Gilead Sciences shares are knocking on the door of a key break above a well-established resistance line. Although there's another major ceiling beyond that one that could disrupt the chart that's admittedly easy to disrupt, there's also a chance that the bears have inflicted enough damage and that the company itself has finally addressed the drug-cost issues that have proven so problematic for the stock's price. * Like McKesson, Gilead shares have been range-bound for several weeks after a two-year spell. It's one reasonably compelling way to end weakness and kick off some progress. * Just above the resistance currently at $67.15 is the 200-day moving average line at $68.14, plotted in white on both stock charts. That line is still a make-or-break level. The key will be making that move at a sustainable pace. * The weekly chart not only serves as a reminder that huge swings in both directions are possible, but that last year's peak around $79 could be where any breakout move finally comes to a close.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 5 Red-Hot IPO Stocks to Buy for the Long Run * 5 Stocks to Buy for $20 or Less * 4 Dow Jones Stocks Ready to Rise Compare Brokers The post 3 Big Stock Charts for Tuesday: McKesson, Dish Network and Gilead Sciences appeared first on InvestorPlace.
- Markit•7 days ago
See what the IHS Markit Score report has to say about Gilead Sciences Inc.
Gilead Sciences Inc NASDAQ/NGS:GILDView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for GILD with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GILD. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold GILD had net inflows of $3.37 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Motley Fool•7 days ago
3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal
Pfizer could be only the first of several to spend billions buying smaller biotech.
- MarketWatch•7 days ago
Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.
- InvestorPlace•8 days ago
5 Top Stock Trades for Tuesday: FB, NFLX, GILD, TSLA
Indices tiptoed higher on Monday, but investors are waiting to hear what the Federal Reserve has to say later this week before making any drastic moves. That's not stopping some companies from pouncing though, as M&A continues to be a theme over the last few weeks. Let's let a deal kick off our top stock trades for Tuesday. Top Stock Trades for Tomorrow 1: Pfizer Click to EnlargePfizer (NYSE:PFE) stock is in the news following its $11.4 billion acquisition of Array Biopharma (NASDAQ:ARRY) for $48 per share. The deal sent the latter up by more than 50%, while the former is trying to breakout over resistance as well.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Top-Rated Biotech Stocks to Invest In Today PFE stock has been a better sell than buy up near $43 to $43.50, and a solid buy down near $40. That said, with shares holding up on news of this deal -- actually eking out a gain on Monday -- and trading north of all three of its major moving averages, it looks okay on the long side.If it can clear $43.50 though, it WILL be setting up as a breakout. Over that and $45 is in sight, with even higher prices possible should PFE push through. Top Stock Trades for Tomorrow 2: Gilead Sciences Click to EnlargeThe PFE deal has biotech trading higher on the day and Gilead Sciences (NASDAQ:GILD) is no exception. Shares are up more than 1% on the day, as GILD stock pushes through its 200-day moving average.The 200-day happens to overlap with $76 range resistance, so perhaps this area knocks the stock down once more. However, if GILD can push through, a run up to $70 is possible. If it is resistance, a decline down to the 50-day is expected, with a possible decline down to uptrend support being possible. Top Stock Trades for Tomorrow 3: Tesla Click to EnlargeShares of Tesla (NASDAQ:TSLA) are moving really well on Monday, up over 5% on the day and up over $225. It puts the 50-day moving average in play currently at $231.45, as well as channel resistance near $235 to $240.Should Tesla rally this far, it would be a logical place to book profits for traders. Above it and former range support between $250 to $260 comes into play. In May that area acted as resistance for TSLA.On a pullback -- either from current levels or after tagging resistance -- see that channel support (blue line) holds. Ideally though, the 20-day will act as support for Tesla. Top Stock Trades for Tomorrow 4: Facebook Click to EnlargeThe big blue box on the Facebook (NASDAQ:FB) chart above represents the gap that was created from the company's disappointing quarterly results 11 months ago.Shares have pushed into this gap twice, in August 2018 and Q2 2019. Neither time has the stock been able to "fill" the gap all the way back up.With FB stock now jumping higher though, is the third time a charm? Maybe. Shares have climbed aggressive off the $160 lows and 200-day moving average, up almost $30 per share in just a few weeks. FB previously topped out near $196 and needs to push through this mark, as well as prior uptrend support (blue line) to fill the gap even more.The 61.8% is at $182.34, while the 50-day is at $182.18. So long as it holds $182, FB looks okay on the long side. Below and it can get a little choppier. Top Stock Trades for Tomorrow 5: Netflix Click to EnlargeNetflix (NASDAQ:NFLX) stock has been highly responsive to this $340 to $342 level. Buyers gobble it up each time NFLX dips in this area of range support. * The 7 Best Tech Stocks to Buy for the Second Half of 2019 That makes it a simple setup, and simple is what we like when it comes to trading. Below the 200-day and traders can cut their losses when dip-buying into this area. Now up a quick 10 points, let's see how NFLX handles the 50-day moving average. Above it could send Netflix to range resistance up near $380.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 7 Best Tech Stocks to Buy for the Second Half of 2019 * 7 Top-Rated Biotech Stocks to Invest In Today * 4 Semiconductor Stocks to Sell Compare Brokers The post 5 Top Stock Trades for Tuesday: FB, NFLX, GILD, TSLA appeared first on InvestorPlace.
- Zacks•8 days ago
AstraZeneca Gives Detailed Data From Calquence Leukemia Study
AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
- Motley Fool•9 days ago
Better Buy: Aurora Cannabis vs. Gilead Sciences
Between this unlikely pair, which stock is the better pick for long-term investors?
- Zacks•11 days ago
GILD vs. ILMN: Which Stock Is the Better Value Option?
GILD vs. ILMN: Which Stock Is the Better Value Option?
- Motley Fool•11 days ago
3 Top Dividend Stocks to Buy in June
Here's why it could be the perfect time to add these income stocks to your portfolio.
- MarketWatch•12 days ago
Amgen, Biogen, Gilead and Novo Nordisk have ‘very high’ capacity for M&A, says Moody’s
Amgen Inc., Biogen Inc., Gilead Inc. and Novo Nordisk A/S all have “very high” capacity for M&A activity, Moody’s Investors Service said in a report published Thursday.
